Literature DB >> 31593447

A Metabolically Stable Boron-Derived Tyrosine Serves as a Theranostic Agent for Positron Emission Tomography Guided Boron Neutron Capture Therapy.

Jiyuan Li1, Yaxin Shi1, Zizhu Zhang2, Hui Liu1, Lixin Lang3, Tong Liu2, Xiaoyuan Chen3, Zhibo Liu1,4.   

Abstract

Boronophenylalanine (BPA) is the dominant boron delivery agent for boron neutron capture therapy (BNCT), and [18F]FBPA has been developed to assist the treatment planning for BPA-BNCT. However, the clinical application of BNCT has been limited by its inadequate tumor specificity due to the metabolic instability. In addition, the distinctive molecular structures between [18F]FBPA and BPA can be of concern as [18F]FBPA cannot quantitate boron concentration of BPA in a real-time manner. In this study, a metabolically stable boron-derived tyrosine (denoted as fluoroboronotyrosine, FBY) was developed as a theranostic agent for both boron delivery and cancer diagnosis, leading to PET imaging-guided BNCT of cancer. [18F]FBY was synthesized in high radiochemical yield (50%) and high radiochemical purity (98%). FBY showed high similarity with natural tyrosine. As shown in in vitro assays, the uptake of FBY in murine melanoma B16-F10 cells was L-type amino acid transporter (LAT-1) dependent and reached up to 128 μg/106 cells. FBY displayed high stability in PBS solution. [18F]FBY PET showed up to 6 %ID/g in B16-F10 tumor and notably low normal tissue uptake (tumor/muscle = 3.16 ± 0.48; tumor/blood = 3.13 ± 0.50; tumor/brain = 14.25 ± 1.54). Moreover, administration of [18F]FBY tracer along with a therapeutic dose of FBY showed high accumulation in B16-F10 tumor and low normal tissue uptake. Correlation between PET-image and boron biodistribution was established, indicating the possibility of estimating boron concentration via a noninvasive approach. At last, with thermal neutron irradiation, B16-F10 tumor-bearing mice injected with FBY showed significantly prolonged median survival without exhibiting obvious systemic toxicity. In conclusion, FBY holds great potential as an efficient theranostic agent for imaging-guided BNCT by offering a possible solution of measuring local boron concentration through PET imaging.

Entities:  

Year:  2019        PMID: 31593447     DOI: 10.1021/acs.bioconjchem.9b00578

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  7 in total

1.  18F-Boramino acid PET/CT in healthy volunteers and glioma patients.

Authors:  Zhu Li; Ziren Kong; Junyi Chen; Jiyuan Li; Nan Li; Zhi Yang; Yu Wang; Zhibo Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-15       Impact factor: 9.236

2.  Evaluation of 3-Borono-l-Phenylalanine as a Water-Soluble Boron Neutron Capture Therapy Agent.

Authors:  Naoya Kondo; Fuko Hirano; Takashi Temma
Journal:  Pharmaceutics       Date:  2022-05-22       Impact factor: 6.525

3.  First-in-human study of an 18F-labeled boramino acid: a new class of PET tracers.

Authors:  Xiaoli Lan; Kevin Fan; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-09       Impact factor: 10.057

Review 4.  The basis and advances in clinical application of boron neutron capture therapy.

Authors:  Huifang He; Jiyuan Li; Ping Jiang; Suqing Tian; Hao Wang; Ruitai Fan; Junqi Liu; Yuyan Yang; Zhibo Liu; Junjie Wang
Journal:  Radiat Oncol       Date:  2021-11-07       Impact factor: 3.481

5.  Larger 18F-fluoroboronotyrosine (FBY) active volume beyond MRI contrast enhancement in diffuse gliomas than in circumscribed brain tumors.

Authors:  Ziren Kong; Zhu Li; Junyi Chen; Wenbin Ma; Yu Wang; Zhi Yang; Zhibo Liu
Journal:  EJNMMI Res       Date:  2022-04-18       Impact factor: 3.434

6.  Boron encapsulated in a liposome can be used for combinational neutron capture therapy.

Authors:  Jiyuan Li; Qi Sun; Chuanjie Lu; Han Xiao; Zhibin Guo; Dongban Duan; Zizhu Zhang; Tong Liu; Zhibo Liu
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

Review 7.  Clinical Viability of Boron Neutron Capture Therapy for Personalized Radiation Treatment.

Authors:  Dominika Skwierawska; José Antonio López-Valverde; Marcin Balcerzyk; Antonio Leal
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.